FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

-	-		_	-				_	_	 	_	_	_
V:	95	hin	nto	n	D	C	2054	q					

**OMB APPROVAL** OMB Number: 3235-0287 Estimated average burden

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* HOLMES EDWARD W							2. Issuer Name and Ticker or Trading Symbol Arcturus Therapeutics Holdings Inc.  [ ARCT ]								of Reportin icable) or r (give title	ing Person(s) to Iss 10% Ow Other (s		vner	
(Last) (First) (Middle) C/O ARCTURUS THERAPEUTICS HOLDINGS						3. Date of Earliest Transaction (Month/Day/Year) 08/01/2023								below			below)		
INC.  10628 SCIENCE CENTER DRIVE, SUITE 250							4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person				
(Street) SAN DIEGO CA 92121					Bul	Form filed by More than One Reporting Person  Rule 10b5-1(c) Transaction Indication												ting	
(City) (State) (Zip)					$ $ $ $ $ $ $ $	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da						Execution Date,			, Transaction Disp Code (Instr. 5)		Dispose	curities Acquired (A) o sed Of (D) (Instr. 3, 4		Benefic	es For ally (D) Following (I) (		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount (A) or (D)		Price	Transa (Instr. 3	tion(s)			30. 4)	
		Т					uired, Dis , options					Owned							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date, T	4. Transactior Code (Instr 8)		5. Numb of Derivati Securiti Acquire (A) or Dispose of (D) (Instr. 3, and 5)	ive les ed	6. Date Exer Expiration I (Month/Day/	ate		le and 7. Title and Amount of Securities Underlying Derivative Set (Instr. 3 and 4		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owners Form: Direct ( or Indir (I) (Instr	Ownership	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				c	Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$34.92	08/01/2023			A		11,869		(1)	08/	/01/2033	Common Stock	11,869	\$0.00	11,869	)	D		
Deferred Stock Units	(2)	08/01/2023			A		3,131		(3)		(3)	Common Stock	3,131	\$0.00	3,131		D		

- 1. Shares underlying the option vest monthly over a one year period from the date of grant; provided however, that the remaining unvested balance will vest and become fully exercisable at the Issuer's 2024 annual meeting of stockholders. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
- 2. Each deferred stock unit is economically equivalent to one share of the Issuer's common stock
- 3. Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer

/s/ Ilan Katz, attorney-in-fact

08/03/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.